is steroid cream good for poison ivy

budesonide asthma steroid

Miami's independent source of local news and culture. Athletes and bodybuilders have been using steroids to increase muscle mass for a long time. Many men, particularly those who participate in sports or who are interested in bodybuilding, use steroids to achieve quick results. Many steroids are sold illegally and come with a slew of negative side effects. So, what are some other safe and legitimate alternatives to steroid abuse? Are you trying to bulk up or lose weight with a legal steroid? Researchers have recently created safe, and legal steroids that can be used daily with no negative side effects.

Is steroid cream good for poison ivy dragon gold glowing

Is steroid cream good for poison ivy

High-dose prescription corticosteroid medicines can reduce the symptoms of a poison ivy, oak, or sumac rash allergic contact dermatitis and sometimes reduce the severity and shorten the length of a rash. Prescription corticosteroids are available as pills, creams, gels, ointments, or shots. Prolonged use of oral and injected corticosteroids can cause serious side effects, such as thinning of the bones osteopenia , slowed growth in children, and increased risk of an ulcer or infection.

Talk with your doctor about your risks when using these medicines. High-dose topical corticosteroids should not be confused with over-the-counter hydrocortisone creams, gels, or ointments, which may soothe itching in mild cases of poison ivy, oak, or sumac rash. These products are not recommended for severe rashes. They are not strong enough and may not be used long enough to work.

They may appear to work for a time, but the rash often suddenly flares up again, sometimes worse than before. Blahd, Jr. Gabica, MD - Family Medicine. Author: Healthwise Staff. Medical Review: William H. This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use.

Learn how we develop our content. To learn more about Healthwise, visit Healthwise. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. You probably won't need medical treatment for a poison ivy rash unless it spreads widely, persists for more than a few weeks or becomes infected. If you're concerned, you'll probably first see your primary care doctor. He or she might refer you to a doctor who specializes in skin disorders dermatologist.

Before your appointment, you may want to list all the medications, supplements and vitamins you take. Also, list questions you'd like to ask your doctor about your poison ivy rash. Examples include:. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. This content does not have an English version. This content does not have an Arabic version. Diagnosis You generally won't need to see your doctor to be diagnosed with a poison ivy rash.

Treatment Poison ivy treatments usually involve self-care methods at home. Request an Appointment at Mayo Clinic. Share on: Facebook Twitter. Show references AskMayoExpert. Contact dermatitis. Mayo Clinic; Kermott CA, et al. Poison ivy rash. Time; Thompson DA.

NAPS STEROIDS

Each patient was provided with a pre-stamped questionnaire to return to our office 1 month after their original office appointment. Enrollees were contacted via telephone if their questionnaires were not received in the expected time frame. We did not evaluate the return rate of appointments for routine recheck due to wide practice variance and this not being necessary for standard of care. Since this was an exploratory study, we did not correct for multiple tests, but all tests that were conducted are reported.

This study was approved by the CoxHealth Institutional Review Board and no post-hoc analyses were undertaken. Information was initially collected from 55 patients meeting criteria for severe poison ivy from April 1, through December 1, Forty-nine of these initial patients completed the study. Enrollment flow of patients into the study can be visualized in Figure 1 ; patients discontinuing intervention were still included in the final analysis.

Patient demographics are delineated in Table 1. At the time of questionnaire receipt or phone call, five of 27 in the short-course arm and one of 22 in the long-course arm reported no improvement with the study treatment. However, no significant difference was found between the groups in compliance with the study treatment, overt improvement of rash, time to improvement of the rash, total number of days to complete resolution, or occurrence of side effects, as can be seen in Table 2.

Of the three patients complaining of side effects, only one stopped treatment secondary to weight gain. Other reported side effects not leading to discontinuation of medication included anger, hyperactivity, insomnia, and nausea. Similarly, no difference was seen between the groups in reoccurrence of rebound rash. One case of recurring rash was located differently from the original rash, making it unclear if it represented a true rash rebound or a new exposure to poison ivy.

Patients receiving the long-course regimen were significantly less likely to utilize other medications Additional treatments utilized by both groups as well as statistical significance calculations for this study question can be seen in Table 3. No comparisons other than those listed were originally identified, collected or analyzed in the statistical analysis of these data.

Contact dermatitis from Toxidendron poison ivy, oak, and sumac is a frequently diagnosed condition in the outpatient primary care setting. Optimal treatment strategy demands provision of cure with maximum reduction in side effects. Expert recommendation has previously been the highest level of evidence found for tapering steroid therapy.

Our study is limited by small sample size leading to lower statistical power , and a non-blinded protocol use of a placebo taper was not feasible within our network resources. The small sample size was the result of a strict adherence to the diagnosis of severe contact dermatitis - all patients in all participating research network practices identified at the time of initial contact with their provider were enrolled over one full poison ivy season.

Small sample size can potentially increase the risk of a false positive result. Since this was an exploratory study, we did not correct for multiple tests, but all tests that were conducted were reported. Despite these limitations, our study suggests that a taper prevents the use of significantly more additional medications, with a relatively low number needed to treat of 3.

Seventy-five percent of those patients using extra medications came from the short-course arm 15 of 20 , and the majority of those patients required extra prescription medication in the form of a longer course of prednisone, intramuscular steroids, or topical steroids.

While the non-blinded nature of our study is a limitation and may have prompted patients in the short-course arm to ask for more medication because they knew the other study arm was receiving an extra amount of steroid, we assumed that patients would return only if they had discomfort or symptoms worrisome enough to them to make taking a medication worth the time and trouble to do so.

To enhance power and effect size, larger randomized, controlled studies are needed, specifically to address the magnitude of effect of extra medication utilization in the prevention of rebound rash. The use of extra over the counter and prescription steroids could then be studied individually. In addition, while the use of topical steroids is recommended as A-level evidence for mild contact dermatitis [ 2 ], treatment options for cases that are more serious but do not yet meet criteria for severe dermatitis are less well-defined and optimal dosing is unknown.

National Center for Biotechnology Information , U. J Clin Med Res. Published online Sep 9. Gabrielle Curtis a, d and Amy C. Lewis b, c. Amy C. Author information Article notes Copyright and License information Disclaimer. Email: moc. Accepted May 5. Copyright , Curtis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been cited by other articles in PMC. Abstract Background Toxidendron poison ivy, oak, and sumac contact dermatitis is a common complaint in the outpatient primary care setting with little evidence-based guidance on best treatment duration. Methods This randomized, controlled trial examined the efficacy and side effects of a 5-day regimen of 40 mg oral prednisone daily short course compared to the same 5-day regimen followed by a prednisone taper of 30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days, and 5 mg daily for 4 days over a total of 15 days long course in patients with severe poison ivy dermatitis.

Results In 49 patients with severe poison ivy, non-adherence rates, rash return, medication side effects, and time to improvement and complete healing of the rash were not significantly different between the two groups. Keywords: Toxidendron, Poison ivy, Contact dermatitis, Steroid taper. Introduction Contact dermatitis, particularly from Toxidendron foliage poison ivy, oak, and sumac , is a common complaint in primary care offices.

Materials and Methods We conducted a randomized, controlled trial of a 5-day regimen short-course arm of oral prednisone 40 mg daily and mg total per patient compared to the same regimen followed by a taper long-course arm of 30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days, and 5 mg daily for 4 days 15 days total administration time and mg total per patient evaluating 49 patients with severe contact dermatitis from poison ivy. Results Information was initially collected from 55 patients meeting criteria for severe poison ivy from April 1, through December 1, Open in a separate window.

Figure 1. Table 1 Patients Demographics. Table 2 Clinical Outcomes. Discussion Contact dermatitis from Toxidendron poison ivy, oak, and sumac is a frequently diagnosed condition in the outpatient primary care setting. Grant Support None. Learn how we develop our content. To learn more about Healthwise, visit Healthwise. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. Corticosteroids for Poison Ivy, Oak, or Sumac.

Topic Overview High-dose prescription corticosteroid medicines can reduce the symptoms of a poison ivy, oak, or sumac rash allergic contact dermatitis and sometimes reduce the severity and shorten the length of a rash. Corticosteroid pills usually prednisone can dramatically reduce the symptoms caused by a strong reaction to poison ivy, oak, or sumac.

Oral corticosteroids generally work better than other forms of these medicines for poison ivy, oak, or sumac. And they are usually taken until the symptoms are gone. How much medicine you take and for how long often depends on how soon you seek help after the rash appears.

Creams, gels, and ointments applied to the skin topical products may help reduce itching and redness. Examples of topical corticosteroids include clobetasol such as Temovate , betamethasone such as Diprolene , and fluticasone such as Cutivate. These types of corticosteroids have no effect on blisters. But they may be useful after blisters have disappeared. They should be used for the recommended amount of time, because the rash can reappear if they are stopped too soon.

None of these products should be used on the face or genitals, because they can cause the skin to become thin and fragile. Shots of triamcinolone are sometimes used when you cannot take corticosteroid pills. Improperly injected corticosteroids can discolor the skin and cause scarring. Current as of October 5,

Come forum is levofloxacin a steroid opinion you

Medium- to high-potency topical corticosteroids are effective for atopic dermatitis and eczema in adults and children, 9 , 10 as well as for phimosis 11 , 12 i. Topical corticosteroids may be effective for other conditions, but the data to support their use are from small, low-level, or uncorroborated studies. Melasma, 15 chronic idiopathic urticaria, 16 infantile acropustulosis, 17 prepubertal labial adhesions, 18 and transdermal testosterone-patch—induced skin irritation 19 fall into this category.

Steroids may differ in potency based on the vehicle in which they are formulated. Some vehicles should be used only on certain parts of the body. Ointments provide more lubrication and occlusion than other preparations, and are the most useful for treating dry or thick, hyperkeratotic lesions. Their occlusive nature also improves steroid absorption. Ointments should not be used on hairy areas, and may cause maceration and folliculitis if used on intertriginous areas e.

Their greasy nature may result in poor patient satisfaction and compliance. Creams are mixes of water suspended in oil. They have good lubricating qualities, and their ability to vanish into the skin makes them cosmetically appealing. Creams are generally less potent than ointments of the same medication, and they often contain preservatives, which can cause irritation, stinging, and allergic reaction. Acute exudative inflammation responds well to creams because of their drying effects.

Creams are also useful in intertriginous areas where ointments may not be used. However, creams do not provide the occlusive effects that ointments provide. Lotions and gels are the least greasy and occlusive of all topical steroid vehicles. Lotions contain alcohol, which has a drying effect on an oozing lesion. Lotions are useful for hairy areas because they penetrate easily and leave little residue.

Gels have a jelly-like consistency and are beneficial for exudative inflammation, such as poison ivy. Gels dry quickly and can be applied on the scalp or other hairy areas and do not cause matting. Foams, mousses, and shampoos are also effective vehicles for delivering steroids to the scalp.

They are easily applied and spread readily, particularly in hairy areas. Foams are usually more expensive. Because hydration generally promotes steroid penetration, applying a topical steroid after a shower or bath improves effectiveness. Simple plastic dressings e. Irritation, folliculitis, and infection can develop rapidly from occlusive dressings, and patients should be counseled to monitor the treatment site closely.

Flurandrenolide Cordran 4 mcg per m 2 impregnated dressing is formulated to provide occlusion. It is beneficial for treating limited areas of inflammation in otherwise difficult-to-treat locations, such as fingertips. This is a useful but imperfect method for predicting the clinical effectiveness of steroids. There are seven groups of topical steroid potency, ranging from ultra high potency group I to low potency group VII.

Table 2 provides a list of topical steroids and available preparations listed by group, formulation, and generic availability. This should be considered when choosing steroid agents. Physicians should also be aware that some generic formulations have been shown to be less or more potent than their brand-name equivalent.

Information from reference Low-potency steroids are the safest agents for long-term use, on large surface areas, on the face or areas of the body with thinner skin, and on children. More potent agents are beneficial for severe diseases and for areas of the body where the skin is thicker, such as the palms and bottoms of the feet.

High- and ultra-high-potency steroids should not be used on the face, groin, axilla, or under occlusion, except in rare situations and for short durations. Once-or twice-daily application is recommended for most preparations. Chronic application of topical steroids can induce tolerance and tachyphylaxis. Ultra-high-potency steroids should not be used for more than three weeks continuously. This intermittent schedule can be repeated chronically or until the condition resolves.

Side effects are rare when low- to high-potency steroids are used for three months or less, except in intertriginous areas, on the face and neck, and under occlusion. The amount of steroid the patient should apply to a particular area can be determined by using the fingertip unit method.

Table 3 describes the number of fingertip units needed to cover specific areas of the body. The amount dispensed and applied should be considered carefully because too little steroid can lead to a poor response, and too much can increase side effects.

Prolonged use of topical corticosteroids may cause side effects Table 4 To reduce the risk, the least potent steroid should be used for the shortest time, while still maintaining effectiveness. The most common side effect of topical corticosteroid use is skin atrophy. All topical steroids can induce atrophy, but higher potency steroids, occlusion, thinner skin, and older patient age increase the risk. The face, the backs of the hands, and intertriginous areas are particularly susceptible.

Resolution often occurs after discontinuing use of these agents, but it may take months. Concurrent use of topical tretinoin Retin-A 0. Topical steroids can also induce rosacea, which may include the eruption of erythema, papules, and pustules. Steroid-induced rosacea occurs when a facial rash is treated with low-potency topical steroids that produce resolution of the lesions.

If the symptoms recur and steroid potency is gradually increased, the rosacea may become refractory to further treatment, making it necessary to discontinue the steroid. This may then induce a severe rebound erythema and pustule outbreak, which may be treated with a day course of tetracycline mg four times daily or erythromycin mg four times daily.

For severe rebound symptoms, the slow tapering of low-potency topical steroids and use of cool, wet compresses on the affected area may also help. The normal presentation of superficial infections can be altered when topical corticosteroids are inappropriately used to treat bacterial or fungal infections. Steroids interfere with the natural course of inflammation, potentially allowing infections to spread more rapidly. The application of high-potency steroids can induce a deep-tissue tinea infection known as a Majocchi granuloma.

Easy bruising. Increased fragility. Stellate pseudoscars. Steroid atrophy. Aggravation of cutaneous infection. Granuloma gluteale infantum. Masked infection tinea incognito. Secondary infections. Contact dermatitis. Delayed wound healing. Hypertrichosis hirsutism.

Perioral dermatitis. Reactivation of Kaposi sarcoma. Rebound flare. Steroid-induced acne. Steroid-induced rosacea. Ocular hypertension. Cushing disease. Hypothalamic-pituitary-adrenal suppression. Aseptic necrosis of the femoral head. Decreased growth rate. Peripheral edema. Adverse effects of topical glucocorticosteroids.

J Am Acad Dermatol. This tinea folliculitis requires oral antifungal therapy. Combinations of antifungal agents and corticosteroids should be avoided to reduce the risk of severe, persistent, or recurrent tinea infections. Topical applications of corticosteroids can also result in hypopigmentation. This is more apparent with darker skin tones, but can happen in all skin types.

Repigmentation often occurs after discontinuing steroid use. Steroids can induce a contact dermatitis in a minority of patients, but many cases result from the presence of preservatives, lanolin, or other components of the vehicle. Non-fluorinated steroids e. Topically applied high- and ultra-high-potency corticosteroids can be absorbed well enough to cause systemic side effects.

Hypothalamic-pituitary-adrenal suppression, glaucoma, septic necrosis of the femoral head, hyperglycemia, hypertension, and other systemic side effects have been reported. According to a postmarketing safety review, the most frequently reported side effects were local irritation 66 percent , skin discoloration 15 percent , and striae or skin atrophy 15 percent.

Topical steroids can induce birth defects in animals when used in large amounts, under occlusion, or for long duration. Food and Drug Administration as pregnancy category C. It is unclear whether topical steroids are excreted in breast milk; as a precaution, application of topical steroids to the breasts should be done immediately following nursing to allow as much time as possible before the next feeding.

Children often require a shorter duration of treatment and a lower potency steroid. Already a member or subscriber? Log in. At the time the article was written, Dr. He received his doctorate of pharmacy from the Nesbitt College of Pharmacy and Nursing and completed residency training and a faculty development fellowship at the University of Pittsburgh Pa.

Margaret Family Medicine Residency Program. Address correspondence to Jonathan D. South St. Reprints are not available from the authors. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. A double-blind randomized trial of 0. Arch Dermatol. Vitiligo: a retrospective comparative analysis of treatment modalities in patients. J Dermatol. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease.

The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid. Br J Dermatol. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. Poison ivy botanical name Toxicodendron radicans is a plant that grows almost everywhere in the United States.

The rash caused by poison ivy is a type of allergic contact dermatitis and starts within 12 hours of contact but may take a few days to fully develop. Typical symptoms include:. The rash typically just covers the area of skin that came into contact with the oil; however, it may be more widespread if caused by pets rubbing against you that have oil on their fur or if lawn clippings contaminated with poison ivy are touched when emptying the mower bag.

The severity of the reaction decreases with age, especially in people who have been exposed to the plant in the past. The rash will usually get better within a couple of weeks, even without treatment. Most cases do not need to be treated by a doctor; however, you should go to the emergency room if you have shortness of breath, trouble swallowing, the rash is on your face or genitals, covers a large area of your body, or if there is swelling.

Widespread rashes may require treatment with a prescription corticosteroid. Rarely, you can also develop a bacterial infection at the rash site. If this happens, you may need a prescription antibiotic. Oral tablets usually prednisone dramatically reduce symptoms in people who have a severe reaction to poison ivy and are usually prescribed short-term. Prolonged use can cause bone changes, skin thinning, an increased risk of infection and stomach ulcers. Topical corticosteroids include clobetasol , betamethasone , or triamcinolone may help reduce itching and redness.

They should be used exactly as your doctor has directed because the rash can reappear if they are stopped too soon. Strong corticosteroid creams are not usually prescribed for use on the face or genitals because they can cause the skin to become thin and fragile.

STEROIDS FROM BRITISH DRAGON

Blahd, Jr. Gabica, MD - Family Medicine. Author: Healthwise Staff. Medical Review: William H. This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content. To learn more about Healthwise, visit Healthwise.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. Corticosteroids for Poison Ivy, Oak, or Sumac. Topic Overview High-dose prescription corticosteroid medicines can reduce the symptoms of a poison ivy, oak, or sumac rash allergic contact dermatitis and sometimes reduce the severity and shorten the length of a rash.

Corticosteroid pills usually prednisone can dramatically reduce the symptoms caused by a strong reaction to poison ivy, oak, or sumac. Oral corticosteroids generally work better than other forms of these medicines for poison ivy, oak, or sumac. And they are usually taken until the symptoms are gone. How much medicine you take and for how long often depends on how soon you seek help after the rash appears.

Creams, gels, and ointments applied to the skin topical products may help reduce itching and redness. Examples of topical corticosteroids include clobetasol such as Temovate , betamethasone such as Diprolene , and fluticasone such as Cutivate.

One case of recurring rash was located differently from the original rash, making it unclear if it represented a true rash rebound or a new exposure to poison ivy. Patients receiving the long-course regimen were significantly less likely to utilize other medications Additional treatments utilized by both groups as well as statistical significance calculations for this study question can be seen in Table 3.

No comparisons other than those listed were originally identified, collected or analyzed in the statistical analysis of these data. Contact dermatitis from Toxidendron poison ivy, oak, and sumac is a frequently diagnosed condition in the outpatient primary care setting. Optimal treatment strategy demands provision of cure with maximum reduction in side effects. Expert recommendation has previously been the highest level of evidence found for tapering steroid therapy.

Our study is limited by small sample size leading to lower statistical power , and a non-blinded protocol use of a placebo taper was not feasible within our network resources. The small sample size was the result of a strict adherence to the diagnosis of severe contact dermatitis - all patients in all participating research network practices identified at the time of initial contact with their provider were enrolled over one full poison ivy season.

Small sample size can potentially increase the risk of a false positive result. Since this was an exploratory study, we did not correct for multiple tests, but all tests that were conducted were reported. Despite these limitations, our study suggests that a taper prevents the use of significantly more additional medications, with a relatively low number needed to treat of 3. Seventy-five percent of those patients using extra medications came from the short-course arm 15 of 20 , and the majority of those patients required extra prescription medication in the form of a longer course of prednisone, intramuscular steroids, or topical steroids.

While the non-blinded nature of our study is a limitation and may have prompted patients in the short-course arm to ask for more medication because they knew the other study arm was receiving an extra amount of steroid, we assumed that patients would return only if they had discomfort or symptoms worrisome enough to them to make taking a medication worth the time and trouble to do so.

To enhance power and effect size, larger randomized, controlled studies are needed, specifically to address the magnitude of effect of extra medication utilization in the prevention of rebound rash. The use of extra over the counter and prescription steroids could then be studied individually. In addition, while the use of topical steroids is recommended as A-level evidence for mild contact dermatitis [ 2 ], treatment options for cases that are more serious but do not yet meet criteria for severe dermatitis are less well-defined and optimal dosing is unknown.

National Center for Biotechnology Information , U. J Clin Med Res. Published online Sep 9. Gabrielle Curtis a, d and Amy C. Lewis b, c. Amy C. Author information Article notes Copyright and License information Disclaimer. Email: moc. Accepted May 5. Copyright , Curtis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been cited by other articles in PMC. Abstract Background Toxidendron poison ivy, oak, and sumac contact dermatitis is a common complaint in the outpatient primary care setting with little evidence-based guidance on best treatment duration. Methods This randomized, controlled trial examined the efficacy and side effects of a 5-day regimen of 40 mg oral prednisone daily short course compared to the same 5-day regimen followed by a prednisone taper of 30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days, and 5 mg daily for 4 days over a total of 15 days long course in patients with severe poison ivy dermatitis.

Results In 49 patients with severe poison ivy, non-adherence rates, rash return, medication side effects, and time to improvement and complete healing of the rash were not significantly different between the two groups. Keywords: Toxidendron, Poison ivy, Contact dermatitis, Steroid taper. Introduction Contact dermatitis, particularly from Toxidendron foliage poison ivy, oak, and sumac , is a common complaint in primary care offices.

Materials and Methods We conducted a randomized, controlled trial of a 5-day regimen short-course arm of oral prednisone 40 mg daily and mg total per patient compared to the same regimen followed by a taper long-course arm of 30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days, and 5 mg daily for 4 days 15 days total administration time and mg total per patient evaluating 49 patients with severe contact dermatitis from poison ivy. Results Information was initially collected from 55 patients meeting criteria for severe poison ivy from April 1, through December 1, Open in a separate window.

Figure 1. Table 1 Patients Demographics. Table 2 Clinical Outcomes. Discussion Contact dermatitis from Toxidendron poison ivy, oak, and sumac is a frequently diagnosed condition in the outpatient primary care setting. Grant Support None.

Conflicts of Interest None on the parts of all parties herein-mentioned. References 1. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. Contact dermatitis: a practice parameter. Allergy Asthma Immunol. Efficacy of topical corticosteroids in nickel-induced contact allergy.

Clin Exp Dermatol. Allergic contact dermatitis: pathophysiology applied to future therapy. Dermatol Ther. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol. Wooldridge WE.